Adagene Inc. Stock Price, News & Analysis

Adagene (Nasdaq: ADAG) has announced a virtual KOL event scheduled for January 25, 2025, at 1:00 PM ET, focusing on their anti-CTLA-4 SAFEbody® ADG126 treatment for advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

The event will feature distinguished experts including Dr. Aurélien Marabelle from Université Paris-Saclay and Drs. Daneng Li and Marwan Fakih from City of Hope. They will discuss the unmet needs in MSS CRC treatment and the importance of CTLA-4 targeting for achieving durable responses in this cold tumor type.

The presentation will include updates on the Phase 1b/2 study of ADG126 (muzastotug) in combination with KEYTRUDA® (pembrolizumab), which will be featured at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. ADG126 is designed to target CTLA-4 on regulatory T cells within the tumor microenvironment, offering potent anti-tumor activity with reduced toxicity.

Adagene presented two posters at SITC's 39th Annual Meeting showcasing new insights on ADG126 (Muzastotug), their masked anti-CTLA-4 SAFEbody®. The data demonstrates improved safety and efficacy profiles compared to ipilimumab, driven by precision masking and novel epitope-dependent antibody-dependent cellular cytotoxicity. Clinical results show promising outcomes when combining ADG126 with pembrolizumab in MSS CRC patients, with four partial responses reported in the 10 mg/kg Q3W combination cohort. The treatment showed lower rates of adverse events compared to standard therapies, with no Grade 3 or higher colitis reported in combination therapy.

Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.

Two posters will be presented on November 9:

• Abstract 506: Comparing the clinical therapeutic index of Muzastotug to its unmasked form (ADG116) as monotherapy or combined with anti-PD-1 therapy.
• Abstract 744: Phase 1b/2 study of Muzastotug combined with Pembrolizumab in advanced/metastatic MSS CRCs.

Both posters will be viewable during lunch (12:15-1:45 PM CST) and at the poster reception (7:10-8:30 PM CST) at the George R. Brown Convention Center. The posters will also be available on Adagene's website.

Adagene Inc. (Nasdaq: ADAG) presented promising results for its anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in combination with KEYTRUDA® (Pembrolizumab) at the ESMO Congress. The phase 1b/2 trial focused on advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) patients. Key findings include:

1. Doubled confirmed partial responses to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases, with a 24% overall response rate.

2. Median progression-free survival of 8.5 months in patients without liver and peritoneal metastases at ADG126 10 mg/kg Q3W dose.

3. 12-month overall survival rates of 74% for patients without liver metastases and 82% for those without liver and peritoneal metastases at 10 mg/kg dose.

4. Maintained safety profile with only 16% Grade 3 TRAEs in patients treated with ADG126 10 mg/kg Q3W combined with pembrolizumab.

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company, has announced its participation in several upcoming investor conferences in New York City this September. The company's management will host investor meetings, and Peter Luo, Ph.D., Adagene's Chairman, CEO, and President of R&D, will present at three major events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6
2. H.C. Wainwright 26th Annual Global Investment Conference on September 9
3. 2024 Cantor Fitzgerald Global Healthcare Conference on September 18

Live webcasts of the presentations will be available on Adagene's website, with replays accessible for at least 30 days. These conferences provide an opportunity for Adagene to showcase its platform-driven approach to discovering and developing novel antibody-based therapies.

Adagene Inc. (Nasdaq: ADAG) reported financial results for H1 2024 and provided corporate updates. Highlights include:

1. ADG126, a masked anti-CTLA-4 SAFEbody, shows potential best-in-class profile in combination with pembrolizumab.

2. Poster presentation planned at ESMO Congress 2024 for ADG126 in metastatic MSS colorectal cancer.

3. Cash balance of $95.7 million funds operations into 2026.

4. Net revenue was nil for H1 2024, compared to $17.3 million in H1 2023.

5. R&D expenses decreased 31% to $14.7 million in H1 2024.

6. Net loss was $17.0 million in H1 2024, compared to $4.1 million in H1 2023.

7. Non-GAAP net loss was $14.5 million in H1 2024.

Adagene has announced a poster presentation at the European Society for Medical Oncology (ESMO) Congress, scheduled for 13-17 September 2024 in Barcelona, Spain.

The presentation will highlight results from an ongoing phase 1b/2 trial of their masked anti-CTLA-4 SAFEbody, ADG126 (muzastotug), in combination with pembrolizumab. The trial focuses on treating patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The poster, titled 'Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC', will be available on Adagene's website following ESMO's embargo policy.

Adagene (Nasdaq: ADAG) will participate in multiple investor conferences in June 2024. CEO and Chairman, Peter Luo, Ph.D., will provide company updates, particularly on the ADG126 SAFEbody® anti-CTLA-4 progress. The Jefferies Global Healthcare Conference in New York City is scheduled for June 5, followed by the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 13. Lastly, the HC Wainwright 2nd Annual Immune Cell Engager Virtual Conference will be held on June 25. Investors can access live webcasts and replays on Adagene's website.